Get in Touch

Assessing the BD&L opportunity of a specific orphan drug

Client Challenge

Understanding the pricing and access potential of the product across the EU5 in its first and subsequent P&R indications.

The biotech had previously identified a product being developed in multiple orphan indications as a target for in-licensing. Although all indications were rare, each had different landscapes, and the product had a different formulation and mode of administration in the third indication.

P4A Solution

P4A assessed the product and then implemented these stages:

  • Disease landscape evaluations and analogue analysis
  • P&R hypotheses development
  • Payer research to validate hypotheses
  • Recommendations

The Successful Outcome

  • Understood the P&R, patient access and competitive landscape for the product in each indication
  • Provided information on list & net pricing potential, levels of access restrictions imposed by the payer and time to access, which were key inputs to the forecasting model
  • Identified impact of the re-formulation / label expansion on P&R and the need for new branding for one indication
  • Identified evidence and market shaping mitigation measures to further optimise the P&R / commercial potential of the product
P4A found additional pockets of opportunity that were not apparent to us previously.
Chief Commercial Officer

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact